>>>ASCIVAR-ASCS allogeneic for intravenous treatment of inflammatory diseases: Rheumatoid arthritis.

ASCIVAR-ASCS allogeneic for intravenous treatment of inflammatory diseases: Rheumatoid arthritis.

This was the first consortium project in which NIMGenetics participated, and was coordinated by TIGenix, a leading company in the cell therapy sector. We participated by providing the consortium with genomic tools for the quality control of therapeutic cells, using the initial design of KaryoNIM®Stem Cells. So far, all genetic stability studies had been performed using conventional, widely validated karyotyping, but with certain limitations. This project made it possible to carry out a comparative study on the effectiveness of this platform against conventional karyotypes when it comes to ensuring the genetic quality of cells destined for therapeutic uses.

2018-12-17T16:57:12+01:0017 September , 2018|